apply now

City of Houston opens applications for 2023 business competition

Small businesses in Houston can apply for the annual Liftoff Houston competition. Photo via liftoffhouston.smapply.org

The City of Houston opened applications for its annual Liftoff Houston Startup Business Plan Competition, which helps local founders bring their months-old companies to new heights.

Now in its 11th year, the competition and educational program awards $10,000 in seed money to three founders after completing a four-month-long workshop series that culminates in a Pitch Day. Winners are named in three categories: Innovation, Product and Service.

Applications must be received by 4 p.m. on Friday, August 4. And Pitch Day will be held on November 18. To be eligible for the competition, applicants must live in Houston and operate their businesses here. Businesses must have only been in operation for less than a year and show verifiable revenue that does not exceed $10,000. Founders who do not meet these criteria are eligible for Liftoff's Educational Pathway track that does not include the competition portion of the program.

“For 11 years, Liftoff Houston has empowered participants to achieve financial mobility through entrepreneurship,” Mayor Sylvester Turner said in a statement. “These participants have become key drivers to the success of Houston’s economy, and they have contributed to our communities by creating jobs and by providing much needed goods and services.”

Liftoff Houston is sponsored by Capital One Bank and administered by the Houston Public Library and the City's Office of Business Opportunity. According to a statement, the program has helped serve historically marginalized populations in Houston. In last year's cohort, 95 of participants identified as people of color, 77 percent were female, 44 percent had no college degree and 54 percent made less than $50,000.

Last year's winners in the Innovation, Product and Service were:

  • Innovation: Aditya Aggarwal, founder of Maritime XR, which aims to supplement conventional maritime training with virtual reality simulations.
  • Product: Hannah Le, founder of RE.STATEMENT, a marketplace for designers to upcycle old fashion into wearable art
  • Service: Natasha Roberts, founder of ActIVate Drip Spa, which provides medical-grade IV drips that help eliminate toxins and aid hydration and recovery

"I wanted to see how far I could go," Le told Innovation Map earlier this year. "I had pitched before, but this was the first time that I was onstage and I just felt like I belonged there."

Le shared more about the founding of RE.STATEMENT and how Liftoff Houston impacted her business in an episode of the Houston Innovators Podcast




Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted